Side skin reactions of multikinase inhibitors in treatment of thyroid cancer

Cover Page

Cite item

Full Text

Abstract

Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.

About the authors

F. S. Sevryukov

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-9756-6275
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

E. V. Borodavina

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-3306-5906
32 nd Botkinsky Dr., Moscow 125284

Р. А. Isaev

National Medical Research Radiology Center, Ministry of Health of Russia

Author for correspondence.
Email: isaev@mrrc.obninsk.ru
ORCID iD: 0000-0001-9831-4814
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

V. V. Polkin

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-0857-321X
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

А. А. Ilyin

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-6581-633X
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

S. V. Vasilkov

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-4423-5640
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

Yu. А. Panaseykin

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-9831-4814
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

D. N. Derbugov

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-4275-4842
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

S. А. Ivanov

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-7689-6032
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

S. О. Podvyaznikov

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0003-1341-0765

Bld. 1, 2/1 Barrikadnaya St., Moscow 125993

Russian Federation

А. D. Kaprin

National Medical Research Radiology Center, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0001-8784-8415
32 nd Botkinsky Dr., Moscow 125284 Russian Federation

References

  1. Thomas L., Lai S.Y., Dong W. et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19(3):251–8. doi: 10.1634/theoncologist.2013-0362.
  2. Strumberg D., Awada A., Hirte H. et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42(4):548–56. doi: 10.1016/j.ejca.2005.11.014.
  3. Lam E.T., Ringle M.D., Kloos R.T. et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323–30. doi: 10.1200/JCO.2009.25.0068.
  4. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505–12. doi: 10.1200/JCO.2005.03.6723.
  5. Escudier B., Eisen T., Stradler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125–34. doi: 10.1056/NEJMoa060655.
  6. Wells S.A. Jr, Robinson B.G., Gagel R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134–41. doi: 10.1200/JCO.2011.35.5040.
  7. Schlumberger M., Elisei R., Müller S. et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017;28(11):2813–9. doi: 10.1093/annonc/mdx479.
  8. Elisei R., Schlumberger M.J., Müller S.P. et al. Cabozantinib in progressive medullary thyroid cancer [published correction appears in J Clin Oncol. 2014;32(17):1864]. J Clin Oncol 2013;31(29):3639–46. doi: 10.1200/JCO.2012.48.4659.
  9. Milling R.V., Grimm D., Krüger M. et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci 2018;19(10):3258. doi: 10.3390/ijms19103258.
  10. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroi cancer. N Engl J Med 2015;372:621–30. doi: 10.1056/NEJMoa1406470.
  11. Tahara M., Kiyota N., Yamazaki T. et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol 2017;7:25. doi: 10.3389/fonc.2017.00025.
  12. Бородавина Е.В., Исаев П.А., Шуринов А.Ю. и др. Эффективность и переносимость ленватиниба при радиойодрезистентном дифференцированном раке щитовидной железы по результатам многоцентрового наблюдательного исследования в Российской Федерации. Опухоли головы и шеи 2020;10(1):65–72. doi: 10.17650/2222-1468-2020- 10-1-65-72.
  13. Lee W.J., Lee J.L., Chang S.E. et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161(5):1045–51. doi: 10.1111/j.1365-2133.2009.09290.x.
  14. McLellan B., Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011;24:396–400. doi: 10.1111/j.1529-8019.2011.01435.x.
  15. Chanprapaph K., Rutnin S., Vachiramon V. Multikinase inhibitorinduced handfoot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 2016;17(4):387–402. doi: 10.1007/s40257-016-0197-1.
  16. Cabanillas M.E., Waguespack S.G., Bronstein Y. et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M.D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588–95. doi: 10.1210/jc.2009-1923.
  17. Kloos R.T., Ringel M.D., Knopp M.V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675–84. doi: 10.1200/JCO.2008.18.2717.
  18. Снеговой А.В., Болотина Л.В., Горбунова В.А. и соавт. Практические рекомендации по коррекции дерматологических реакций у пациентов, получающих терапию ингибиторами EGFR. Злокачественные опухоли 2016;(4, спецвыпуск 2):428–33. [Snegovoy A.V., Bolotina L.V., Gorbunova V.A. et al. Practical recommendations for the correction of dermatological reactions in patients receiving therapy with EGFR inhibitors. Zlokachestvennye opukholi = Malignant tumors 2016;(4 Special Issue 2):428–33. (In Russ.)]. DOI: 10.18027/ 2224-5057-2016-4s2-428-433.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.